Comparison between the cranial magnetic resonance imaging features of neuromyelitis optica spectrum disorder versus multiple sclerosis in Taiwanese patients
© Liao et al.; licensee BioMed Central Ltd. 2014
- Received: 28 April 2014
- Accepted: 4 November 2014
- Published: 30 November 2014
Neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) are inflammatory diseases of the central nervous system with different pathogenesis, brain lesion patterns, and treatment strategies. However, it is still difficult to distinguish these two disease entities by neuroimaging studies. Herein, we attempt to differentiate NMOSD from MS by comparing brain lesion patterns on magnetic resonance imaging (MRI).
The medical records and cranial MRI studies of patients with NMOSD diagnosed according to the 2006 Wingerchuk criteria and the presence of anti-aquaporin 4 (anti-AQP4) antibodies, and patients with MS diagnosed according to the Poser criteria, were retrospectively reviewed.
Twenty-five NMOSD and 29 MS patients were recruited. The NMOSD patients became wheelchair dependent earlier than MS patients (log rank test; P = 0.036). Linear ependymal (28% vs. 0%, P = 0.003) and punctate lesions (64% vs. 28%, P = 0.013) were more frequently seen in NMOSD patients. Ten NMOSD patients (40%) had brain lesions that did not meet the Matthews criteria (MS were separated from NMOSD by the presence of at least 1 lesion adjacent to the body of the lateral ventricle and in the inferior temporal lobe; or the presence of a subcortical U-fiber lesion or a Dawson finger-type lesion). The different image patterns of NMOSD didn’t correlate with the clinical prognosis. However, NMOSD patients with more (≧10) brain lesions at onset became wheelchair dependence earlier than those with fewer (<10) brain lesions (log rank test; P < 0.001).
The diagnostic sensitivity of NMOSD criteria can be increased to 56% by combining the presence of linear ependymal lesions with unmet the Matthews criteria. The prognoses of NMOSD and MS are different. A specific imaging marker, the linear ependymal lesion, was present in some NMOSD patients. The diagnosis of NMOSD can be improved by following the evolution of this imaging feature when anti-AQP4 antibody test results are not available.
- Neuromyelitis optica
- Multiple sclerosis
- Anti-aquaporin 4 antibody
- Magnetic resonance imaging
Neuromyelitis optica (NMO) is an inflammatory disease mainly characterized by optic neuritis (ON) and longitudinally extensive spinal cord lesions (LESCLs) ,. It displayed relapsing and remitting disease course and central nervous system (CNS) inflammation which is similar to Asian or optico-spinal form multiple sclerosis (OSMS).
The discovery of NMO biomarker anti-aquaporin-4 (anti-AQP4) antibody clearly separates these two diseases into different entities -. Anti-AQP4 antibody plays an important role in the pathogenesis of NMO. It is reported in around 61% ~ 90% of patients with NMO and in only 0% ~ 9% of MS patients -. Typical LESCLs are rarely seen in the patients with multiple sclerosis (MS). This clear distinction suggests that NMO and MS could be two different CNS inflammatory disorders with respect to their immunopathogenesis ,.
Some patients with anti-AQP4 antibody had recurrent optic neuritis, recurrent myelitis, optic neuritis and myelitis associated with systemic autoimmune disease or the brain lesions, rather than the typical features of optic neuritis and LESCLs. Those patients are regarded as having NMO spectrum disorder (NMOSD) ,. The reported frequency of brain involvement in NMO patients ranges from 5% to 89% -. The brain lesions of NMOSD also become temporally and spatially disseminated, as do those of MS. Around 5.6% ~ 42% of brain lesions in NMOSD fulfill the Barkhof magnetic resonance imaging (MRI) criteria ,,,,,. Although Matthews et al. have proposed criteria to distinguish NMOSD from MS by identifying characteristic cerebral lesions for NMOSD in the hypothalamus and periaqueductal area -,,-, validation, especially in Asians, is still required ,,. Given that the pathogenesis and treatment of NMOSD and MS are different, the standard immunomodulation therapy for MS, such as interferon, may be ineffective to control relapses or disease progression of NMO ,-. Specific imaging markers are needed to distinguish NMOSD from MS particularly in the early stage. By comparing the cranial magnetic resonance imaging (MRI) characteristics of NMOSD with those of MS, we found linear ependymal and punctate lesions specifically occurring in patients with NMOSD, whereas corpus callosum lesions are frequently seen in patients with MS. This clear difference in imaging features will be helpful in distinguishing NMOSD from MS in clinical practice.
We retrospectively reviewed the medical records of all NMO or MS patients with one or more episodes of CNS inflammatory disease treated between January 2009 and January 2014 at Chang Gung Memorial Hospital-Linkou Medical Center, a tertiary referral medical center in the northern Taiwan. A CNS inflammatory episode was defined as the presence of patient-reported symptoms or objectively observed typical signs of an acute inflammatory event including optic neuritis and myelitis in the CNS, with duration of at least 24 hours . Patients with optic neuritis is diagnosed as having typical clinical symptoms of blurred vision and visual-field defect with evidence of a relative afferent pupillary defect (by neurological examination or prolonged p100 wave of visual evoke potential study) , or by the diagnosis of ophthalmologists. At the time of the attack, all patients were tested for anti-AQP4 antibodies to confirm the diagnosis. The protocol of this study was approved by the Institutional Review Board of Chang Gung Memorial Hospital and University (License no. 101-3410B).
Diagnosis of NMOSD and MS
The diagnoses of NMO and MS were according to the revised 2006 Wingerchuk criteria  and Poser criteria , respectively. The NMO patients who also had brain lesions were diagnosed as NMOSD . All NMOSD patients had both optic neuritis and myelitis during the follow-up periods. The serum anti-AQP4 antibodies were detected using an enzyme-linked immunosorbent assay (ELISA) system according to the manufacturer's instructions (RSR/Kronus, Cardiff, UK) , and a level greater than 5 U/mL was considered seropositive. There are reports of combined autoimmune disease (myasthenia gravis or Sjögren’s syndrome) with NMOSD -. To simplify the study population, patients with Sjögren’s syndrome, systemic lupus erythematosus, rheumatoid arthritis, vasculitis, myasthenia gravis or underlying malignancies were excluded in our study.
Collection of clinical and imaging data
Criteria for the evaluation of diagnostic accuracy
To distinguish MS from NMOSD on cranial MRIs, Matthews et al. proposed the presence of at least 1 lesion adjacent to the body of the lateral ventricle and in the inferior temporal lobe; or the presence of a subcortical U-fiber lesion or periventricular Dawson's finger lesion . The sensitivity, specificity, positive predictive value, and negative predictive value of using unmet the Matthews criteria and the presence of linear ependymal lesions to distinguish NMOSD from MS were tested in our patients.
Statistical analyses were performed using Statistical Program for Social Sciences (SPSS) statistical software (version 13.0; Chicago, IL, USA). Fisher exact test was used to compare clinical symptoms and imaging features of NMOSD with those of MS. Non-categorical variables are expressed as the means ± standard deviation (SD) and compared by two-sample t-tests. Survival curves were estimated by the Kaplan–Meier method. Time zero for the survival analysis was taken as the date of the first CNS inflammatory episode. The primary end-point was the time when patients became wheelchair dependent (EDSS = 7). For patients who remained ambulatory, the follow-up period ended on the date of the last visit. All P values were two-tailed, and a P value less than 0.05 was considered statistically significant.
Demographic data of evaluable NMOSD and MS patients during the follow-up period
NMOSD (n = 25)
MS (n = 29)
Age at 1st attack (years old)
37.8 ± 13.6
33.7 ± 9.2
3 : 22
7 : 22
Symptoms during the study period
Sensory disturbance (%)
Blurred vision (%)
Consciousness change (%)†
Urine/stool retention (%)
Polyuria >3000 ml/day (%)
Diabetes mellitus (%)
Thyroid dysfunction (%)
Respiratory failure (%)
Follow-up duration (months)
129.0 ± 69.5
77.6 ± 64.2
Annual relapse rate (%)
65.0 ± 50.1
54.4 ± 47.3
AQP4 antibody (%)
Long term steroid, IST and DMT
Steroid + Azathioprine
There were 40 brain MRI studies in 25 NMOSD patients and 54 brain MRI studies in 29 MS patients at relapses. Thirty (75%) relapsing episodes in NMOSD group received high dose (500 ~ 1000 mg methylprednisolone/day) intravenous steroid therapies, while 29 (54%) relapsing episodes in MS group received the same treatment. Ten (25%) NMOSD patients had optic neuritis at their first disease attack and five patients received pulse therapy. On the other hand, only five (17.2%) MS patients had optic neuritis as their first clinical attack and three of them received pulse therapy during attack. For the long-standing immunological treatment, twenty-two (88%) NMOSD patients received oral steroid, and five (20%) took oral steroid and azathioprine concurrently. Only eight (27.6%) MS patients received oral steroid treatment. Ten (34.5%) MS patients received interferon beta, one (3.4%) had copaxone, and nine (31%) took fingolimod. Some NMOSD patients were diagnosed as OSMS before testing anti-AQP4 antibody and three patients still received treatment with interferon beta and copaxone (Table 1).
Brain magnetic resonance imaging findings of evaluable NMOSD and MS patients
NMOSD (n = 25)
MS (n = 29)
Number of MRI studies
Location of lesions
Juxtacortical region (%)
Subcortical region (%)
Basal ganglion (%)
Periventricular region (%)
Temporal lobe (%)
Central/dorsal medulla (%)
Corpus callosum (%)
Fit McDonald criteria (DIS)
Fit Matthews criteria†
U fiber lesion (%)
Dawson finger lesion (%)
Tumefactive lesion >3 cm (%)
Punctate lesion (%)
Linear ependymal lesion (%)
Ependymal dot lesion (%)
Diagnosis of NMOSD using different MRI criteria
Positive predictive value
Negative predictive value
1. Linear ependymal lesions
2. Unmet Matthews criteria*
3. 1 and 2
There were six (24%) and nineteen (76%) NMOSD patients had abnormal MRI studies at the first clinical attacks and during the follow-up periods, respectively. The annual relapse rate (0.614 ± 0.455 vs. 0.661 ± 0.526, P = 0.846) and the possibility of wheelchair dependent during the follow-up periods are similar between them (log rank test; P = 0.401).
We found that 6 (24%), 7 (28%), and 12 (48%) NMOSD patients demonstrated brain images fitting the characteristics of punctate lesion, linear ependymal lesion, and demyelination like lesion, respectively. The different image patterns did not significantly correlate with their clinical prognosis. The time to become wheelchair dependent were similar among those three groups (log rank test; P = 0.271). The annual relapse rate of linear ependymal group was possibly higher than demyelination group (0.93 ± 0.61 vs. 0.46 ± 0.40, P = 0.060).
In our series, brain lesions became apparent in 81% of NMOSD patients during the follow-up periods. Symmetric linear ependymal lesions were an imaging feature in about one fourth (7/25) of NMOSD patients with brain lesions but in none of the MS patients. This MRI feature could therefore be used to distinguish NMOSD from MS with a high specificity (100%) but a low sensitivity (24%). We proposed that combining the presence of ependymal lesions with unmet the Matthews criteria would increase the sensitivity of the criteria to differentiate NMOSD from MS (56%), while maintaining their high specificity (100%), high positive predictive value (100%), and high negative predictive value (73%).
The frequency of brain involvement in NMO differs between Eastern and Western countries -. Brain lesions developed in more than 60% of NMO patients in studies from Japan , and Korea , and in less than 30% of NMO patients in studies from France , Italy , and the Caribbean . Moreover, the distribution of brain lesions in NMOSD differs as well. In a study from the UK , few NMO patients had brains with Dawson’s finger-type lesions (0%), subcortical U-fiber lesions (0%), inferior temporal lobe lesions (19%), and periventricular lesions (23%), whereas Korean and Japanese NMOSD patients had brains with more periventricular lesions (40%) and ovoid shaped brain lesions (31.6%), respectively ,. Similar to findings in other Asian countries, our results showed Dawson’s finger type (ovoid) lesions (44%), U-fiber shaped lesions (48%), inferior temporal lesions (36%), and periventricular lesions (60%) were frequently present in NMOSD ,. Although Matthews et al. showed that periventricular, inferior temporal lobe, and U-fiber or Dawson’s finger-type lesions could be very sensitive (>90%) markers for distinguishing MS from NMOSD in UK populations, we showed that they were less sensitive in Taiwanese patients. However, by combining the presence of linear ependymal lesions with unmet the Matthews criteria, we could increase the sensitivity of these criteria from 40% to 56%. It is still uncertain whether genetic or environmental factors contribute to differences in brain lesion distribution.
The characteristic linear ependymal lesions of NMOSD in this study may be explained by the spatial pattern of AQP4, which is mainly expressed in astrocytes in the optic nerve, spinal cord, hypothalamus, and periependymal area in contact with CSF ,. In a pathological study of rats, the AQP4 protein was abundant in glial cells bordering the subarachnoid space and ventricles , which is consistent with the distribution of brain lesions in our NMO patients. Moreover, in support of this speculation, Pittock et al. noted that the locations of NMO brain lesions are associated with structures expressing high levels of AQP4 . Other studies also reported similar periependymal brain lesions in NMOSD patients ,,,,,. Anti-AQP4 antibodies may penetrate the blood–brain barrier, bind to these AQP4-rich regions, and then initiate downstream immunopathological cascades responsible for the development of linear inflammatory lesions in the periependymal tissue of NMOSD patients. Thus, the identification of “linear ependymal lesions” on cranial MRI could be a useful imaging characteristic for identifying NMOSD.
The number of brain MRI lesions in the patients with clinically isolated syndromes (CIS) may predict the development of MS and correlate with disability status after 20 years . Our study also shows the number of brain lesions at onset is an important prognostic factor for NMOSD. NMOSD patients that had 10 or more (≧10) brain lesions on their first MRI may be bound to wheelchairs more rapidly than those with fewer (<10) brain lesions, indicating the application of high potency immunosuppression on this group of patients.
In the present study, a few clinical features were found to distinguish between these two diseases. NMOSD patients with brain lesions more frequently had symptoms of optic neuritis and severe myelitis including blurred vision, sensory disturbance, weakness, and urine/stool retention, while MS patients more frequently had diplopia and dysphagia/dysarthria. Hiccup is reported to be a unique clinical presentation of NMO in patients with periaqueductal lesions . Both of our two patients with hiccup also had linear ependymal lesions in the periaqueductal region. One study also shows that endocrinopathies like amenorrhea, diabetes insipidus, and hypothyroidism develop in patients with recurrent optic neuromyelitis . In this study, hiccup and polyuria (>3000 ml/d) were only seen in NMOSD patients, but because the patient number was too small, this difference between NMOSD patients and MS patients was not statistically significant. The natural history of untreated NMO is significantly worse than that of MS ,. The 5-year survival rate of NMO patients was only 68% in an earlier study . Similarly in our study, five NMOSD patients had respiratory failure during the follow-up periods and two of them died from pneumonia and sepsis around 8 years and 23 years after the first symptoms onset, whereas none of our MS patients had these serious complications. The greater likelihood of wheelchair dependence in NMOSD patients is probably due to longitudinally extensive and greater spinal cord involvement.
This retrospective study may suffer from recruitment bias as a result of the small study population, and the treatment and follow-up durations were inconsistent in both groups. Nevertheless, in our study, prognosis was poorer in NMOSD patients than MS patients. A characteristic imaging marker, linear ependymal lesions, was only present in NMOSD patients but not MS patients. Thus, the differentiation of NMOSD from MS can be improved by closely monitoring the evolution of this image marker.
In summary, NMOSD patients became wheelchair dependence earlier than MS patients. Furthermore, NMOSD patients who had more (≧10) brain lesions on their first MRI had a worse prognosis than those with fewer (<10) brain lesions. A specific imaging marker, the linear ependymal lesion, was present in some NMOSD patients. The diagnostic sensitivity of NMOSD criteria can be increased by combining the presence of linear ependymal lesions with unmet the Matthews criteria.
The Institutional Review Boards of the Chang Gung Memorial Hospital waived the need for individual informed consent because all data were anonymized and de-identified prior to analysis.
MFL: reviewing and evaluating cranial images, analysis and interpretation of data, drafting the manuscript. RKL, CCH, HSC, YRW, CMC, CCC, and HCK: collect of the patients, analysis and interpretation of patients’ image and clinical data. KHC and LSR: analysis and interpretation of data, drafting the manuscript, revising manuscript critically for important intellectual content and contributions to conception and design. All authors read and approved the final manuscript.
We wish to thank Miss Yu-Lin Hung for her help in the preparation of the pictures.
- de Seze J: Neuromyelitis optica. Arch Neurol. 2003, 60: 1336-1338.View ArticlePubMedGoogle Scholar
- Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG: Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006, 66: 1485-1489. 10.1212/01.wnl.0000216139.44259.74.View ArticlePubMedGoogle Scholar
- Kira J: Neuromyelitis optica and asian phenotype of multiple sclerosis. Ann N Y Acad Sci. 2008, 1142: 58-71. 10.1196/annals.1444.002.View ArticlePubMedGoogle Scholar
- Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG: A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004, 364: 2106-2112. 10.1016/S0140-6736(04)17551-X.View ArticlePubMedGoogle Scholar
- Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, Watanabe S, Shiga Y, Kanaoka C, Fujimori J, Sato S, Itoyama Y: Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007, 130: 1235-1243. 10.1093/brain/awm062.View ArticlePubMedGoogle Scholar
- Saiz A, Zuliani L, Blanco Y, Tavolato B, Giometto B, Graus F: Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J Neurol. 2007, 254: 1233-1237. 10.1007/s00415-007-0509-8.View ArticlePubMedGoogle Scholar
- Jarius S, Franciotta D, Bergamaschi R, Wright H, Littleton E, Palace J, Hohlfeld R, Vincent A: NMO-IgG in the diagnosis of neuromyelitis optica. Neurology. 2007, 68: 1076-1077. 10.1212/01.wnl.0000256822.01222.bd.View ArticlePubMedGoogle Scholar
- Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG: The spectrum of neuromyelitis optica. Lancet Neurol. 2007, 6: 805-815. 10.1016/S1474-4422(07)70216-8.View ArticlePubMedGoogle Scholar
- Jacob A, McKeon A, Nakashima I, Sato DK, Elsone L, Fujihara K, de Seze J: Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2013, 84: 922-930. 10.1136/jnnp-2012-302310.View ArticlePubMedGoogle Scholar
- Li Y, Xie P, Lv F, Mu J, Li Q, Yang Q, Hu M, Tang H, Yi J: Brain magnetic resonance imaging abnormalities in neuromyelitis optica. Acta Neurol Scand. 2008, 118: 218-225. 10.1111/j.1600-0404.2008.01012.x.View ArticlePubMedGoogle Scholar
- Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG: Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006, 63: 390-396. 10.1001/archneur.63.3.390.View ArticlePubMedGoogle Scholar
- Wang F, Liu Y, Duan Y, Li K: Brain MRI abnormalities in neuromyelitis optica. Eur J Radiol. 2011, 80: 445-449. 10.1016/j.ejrad.2010.06.024.View ArticlePubMedGoogle Scholar
- Kim JE, Kim SM, Ahn SW, Lim BC, Chae JH, Hong YH, Park KS, Sung JJ, Lee KW: Brain abnormalities in neuromyelitis optica. J Neurol Sci. 2011, 302: 43-48. 10.1016/j.jns.2010.12.001.View ArticlePubMedGoogle Scholar
- Kim W, Park MS, Lee SH, Kim SH, Jung IJ, Takahashi T, Misu T, Fujihara K, Kim HJ: Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler. 2010, 16: 1229-1236. 10.1177/1352458510376640.View ArticlePubMedGoogle Scholar
- Chan KH, Tse CT, Chung CP, Lee RL, Kwan JS, Ho PW, Ho JW: Brain involvement in neuromyelitis optica spectrum disorders. Arch Neurol. 2011, 68: 1432-1439. 10.1001/archneurol.2011.249.View ArticlePubMedGoogle Scholar
- Matsushita T, Isobe N, Piao H, Matsuoka T, Ishizu T, Doi H, Masaki K, Yoshiura T, Yamasaki R, Ohyagi Y, Kira J: Reappraisal of brain MRI features in patients with multiple sclerosis and neuromyelitis optica according to anti-aquaporin-4 antibody status. J Neurol Sci. 2010, 291: 37-43. 10.1016/j.jns.2010.01.009.View ArticlePubMedGoogle Scholar
- Cabrera-Gomez JA, Quevedo-Sotolongo L, Gonzalez-Quevedo A, Lima S, Real-Gonzalez Y, Cristofol-Corominas M, Romero-Garcia K, Ugarte-Sanchez C, Jordan-Gonzalez J, de la Nuez JE, Lahera JG, Tellez R, Pedroso-Ibañez I, Roca RR, Cabrera-Núñez AY: Brain magnetic resonance imaging findings in relapsing neuromyelitis optica. Mult Scler. 2007, 13: 186-192. 10.1177/1352458506070725.View ArticlePubMedGoogle Scholar
- Collongues N, Marignier R, Zephir H, Papeix C, Blanc F, Ritleng C, Tchikviladze M, Outteryck O, Vukusic S, Fleury M, Fontaine B, Brassat D, Clanet M, Milh M, Pelletier J, Audoin B, Ruet A, Lebrun-Frenay C, Thouvenot E, Camu W, Debouverie M, Créange A, Moreau T, Labauge P, Castelnovo G, Edan G, Le Page E, Defer G, Barroso B, Heinzlef O, et al: Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology. 2010, 74: 736-742. 10.1212/WNL.0b013e3181d31e35.View ArticlePubMedGoogle Scholar
- Asgari N, Lillevang ST, Skejoe HP, Falah M, Stenager E, Kyvik KO: A population-based study of neuromyelitis optica in Caucasians. Neurology. 2011, 76: 1589-1595. 10.1212/WNL.0b013e3182190f74.View ArticlePubMedPubMed CentralGoogle Scholar
- Downer JJ, Leite MI, Carter R, Palace J, Kuker W, Quaghebeur G: Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete?. Neuroradiology. 2012, 54: 279-285. 10.1007/s00234-011-0875-x.View ArticlePubMedGoogle Scholar
- Nakashima I, Fujihara K, Miyazawa I, Misu T, Narikawa K, Nakamura M, Watanabe S, Takahashi T, Nishiyama S, Shiga Y, Sato S, Weinshenker BG, Itoyama Y: Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry. 2006, 77: 1073-1075. 10.1136/jnnp.2005.080390.View ArticlePubMedPubMed CentralGoogle Scholar
- Ito S, Mori M, Makino T, Hayakawa S, Kuwabara S: "Cloud-like enhancement" is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol. 2009, 66: 425-428. 10.1002/ana.21753.View ArticlePubMedGoogle Scholar
- Sahraian MA, Moinfar Z, Khorramnia S, Ebrahim MM: Relapsing neuromyelitis optica: demographic and clinical features in Iranian patients. Eur J Neurol. 2010, 17: 794-799. 10.1111/j.1468-1331.2009.02928.x.View ArticlePubMedGoogle Scholar
- Ghezzi A, Bergamaschi R, Martinelli V, Trojano M, Tola MR, Merelli E, Mancardi L, Gallo P, Filippi M, Zaffaroni M, Comi G: Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica. J Neurol. 2004, 251: 47-52. 10.1007/s00415-004-0271-0.View ArticlePubMedGoogle Scholar
- Cabre P, Heinzlef O, Merle H, Buisson GG, Bera O, Bellance R, Vernant JC, Smadja D: MS and neuromyelitis optica in Martinique (French West Indies). Neurology. 2001, 56: 507-514. 10.1212/WNL.56.4.507.View ArticlePubMedGoogle Scholar
- Wang KC, Lee CL, Chen SY, Lin KH, Tsai CP: Prominent brainstem symptoms/signs in patients with neuromyelitis optica in a Taiwanese population. J Clin Neurosci. 2011, 18: 1197-1200. 10.1016/j.jocn.2010.12.052.View ArticlePubMedGoogle Scholar
- Cabrera-Gomez JA, Kister I: Conventional brain MRI in neuromyelitis optica. Eur J Neurol. 2012, 19: 812-819. 10.1111/j.1468-1331.2011.03565.x.View ArticlePubMedGoogle Scholar
- Lu Z, Zhang B, Qiu W, Kang Z, Shen L, Long Y, Huang J, Hu X: Comparative brain stem lesions on MRI of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. PLoS One. 2011, 6: e22766-10.1371/journal.pone.0022766.View ArticlePubMedPubMed CentralGoogle Scholar
- Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA: Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol. 2006, 63: 964-968. 10.1001/archneur.63.7.964.View ArticlePubMedGoogle Scholar
- Matthews L, Marasco R, Jenkinson M, Kuker W, Luppe S, Leite MI, Giorgio A, De Stefano N, Robertson N, Johansen-Berg H, Evangelou N, Palace J: Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology. 2013, 80: 1330-1337. 10.1212/WNL.0b013e3182887957.View ArticlePubMedPubMed CentralGoogle Scholar
- Qiu W, Raven S, Wu JS, Bundell C, Hollingsworth P, Carroll WM, Mastaglia FL, Kermode AG: Hypothalamic lesions in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2011, 82: 819-822. 10.1136/jnnp.2009.198192.View ArticlePubMedGoogle Scholar
- Zhang Y, Dong R, Fan H, Li S, Geng D: Hypothalamus syndrome in opticospinal multiple sclerosis. AJNR Am J Neuroradiol. 2011, 32: E153-E155. 10.3174/ajnr.A2278.View ArticlePubMedGoogle Scholar
- Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, Du Pasquier RA, Polman CH, Sorensen PS, Hemmer B: EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010, 17: 1019-1032. 10.1111/j.1468-1331.2010.03066.x.View ArticlePubMedGoogle Scholar
- Papadopoulos MC, Verkman AS: Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012, 11: 535-544. 10.1016/S1474-4422(12)70133-3.View ArticlePubMedPubMed CentralGoogle Scholar
- Papeix C, Vidal JS, de Seze J, Pierrot-Deseilligny C, Tourbah A, Stankoff B, Lebrun C, Moreau T, Vermersch P, Fontaine B, Lyon-Caen O, Gout O: Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler. 2007, 13: 256-259. 10.1177/1352458506070732.View ArticlePubMedGoogle Scholar
- Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011, 69: 292-302. 10.1002/ana.22366.View ArticlePubMedPubMed CentralGoogle Scholar
- Beck RW, Cleary PA, Anderson MM, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR: A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992, 326: 581-588. 10.1056/NEJM199202273260901.View ArticlePubMedGoogle Scholar
- Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983, 13: 227-231. 10.1002/ana.410130302.View ArticlePubMedGoogle Scholar
- Hayakawa S, Mori M, Okuta A, Kamegawa A, Fujiyoshi Y, Yoshiyama Y, Mitsuoka K, Ishibashi K, Sasaki S, Hattori T, Kuwabara S: Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J Neuroimmunol. 2008, 196: 181-187. 10.1016/j.jneuroim.2008.03.009.View ArticlePubMedGoogle Scholar
- Leite MI, Coutinho E, Lana-Peixoto M, Apostolos S, Waters P, Sato D, Melamud L, Marta M, Graham A, Spillane J, Villa AM, Callegaro D, Santos E, da Silva AM, Jarius S, Howard R, Nakashima I, Giovannoni G, Buckley C, Hilton-Jones D, Vincent A, Palace J: Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology. 2012, 78: 1601-1607. 10.1212/WNL.0b013e31825644ff.View ArticlePubMedPubMed CentralGoogle Scholar
- Kim SM, Waters P, Vincent A, Kim SY, Kim HJ, Hong YH, Park KS, Min JH, Sung JJ, Lee KW: Sjogren's syndrome myelopathy: spinal cord involvement in Sjogren's syndrome might be a manifestation of neuromyelitis optica. Mult Scler. 2009, 15: 1062-1068. 10.1177/1352458509106636.View ArticlePubMedGoogle Scholar
- Yau GSK, Lee JWY, Chan TTK, Yuen CYF: Neuromyelitis optica spectrum disorder in a Chinese woman with ocular myasthenia gravis: first reported case in the Chinese population. Neuro-Ophthalmology. 2014, 40: 140-144. 10.3109/01658107.2013.879903.View ArticleGoogle Scholar
- Tsang S, Yau GS, Yuen CY, Lee JW: A Chinese lady with combine neuromyelitis optica and Sjögren's Syndrome: a case report. J Neurophysiol Neurol Dis. 2013, 1: 1-4.Google Scholar
- Lisanti CJ, Asbach P, Bradley WG: The ependymal "Dot-Dash" sign: an MR imaging finding of early multiple sclerosis. AJNR Am J Neuroradiol. 2005, 26: 2033-2036.PubMedGoogle Scholar
- Chen Z, Feng F, Yang Y, Li J, Ma L: MR imaging findings of the corpus callosum region in the differentiation between multiple sclerosis and neuromyelitis optica. Eur J Radiol. 2012, 81: 3491-3495. 10.1016/j.ejrad.2012.02.010.View ArticlePubMedGoogle Scholar
- Amiry-Moghaddam M, Ottersen OP: The molecular basis of water transport in the brain. Nat Rev Neurosci. 2003, 4: 991-1001. 10.1038/nrn1252.View ArticlePubMedGoogle Scholar
- Nielsen S, Nagelhus EA, Amiry-Moghaddam M, Bourque C, Agre P, Ottersen OP: Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci. 1997, 17: 171-180.PubMedGoogle Scholar
- Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, Thompson AJ, Miller DH: Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008, 131: 808-817. 10.1093/brain/awm329.View ArticlePubMedGoogle Scholar
- Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y: Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology. 2005, 65: 1479-1482. 10.1212/01.wnl.0000183151.19351.82.View ArticlePubMedGoogle Scholar
- Vernant JC, Cabre P, Smadja D, Merle H, Caubarrere I, Mikol J, Poser CM: Recurrent optic neuromyelitis with endocrinopathies: a new syndrome. Neurology. 1997, 48: 58-64. 10.1212/WNL.48.1.58.View ArticlePubMedGoogle Scholar
- Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG: The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999, 53: 1107-1114. 10.1212/WNL.53.5.1107.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.